Targeted Antibodies Antibody–Drug Conjugates (ADCs)An antibody–drug conjugate is an antibody linked to an anti-cancer drug. The antibody targets and binds to cancer cells – delivering the “toxic” drug directly to the
Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body’s natural defenses to fight cancer. It uses substances made by the body or in a
South Korea-based LG Chem Life Sciences and U.K.-based Avacta Group have moved forward in their Affimer therapeutics partnership. Avacta has successfully generated a large number of Affimer proteins that bind
Drug developer Avacta, which is working on cures for lung, breast, gastric and bowel cancer, said it has taken an important step towards further “substantial” milestone payments from the drug
Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has provided an update on the Affimer® therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean
In this free webinar, Principal Assay Scientist Dr. Amanda Nicholl presented data from the recently published paper in Biotechniques, ‘Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics’. The use
Avacta Group (LON:AVCT) 12-month results to July 2019 highlight ongoing momentum, as evidenced by three new partnerships (LG Chem, ADC Therapeutics and New England Biolabs), advancement of its pipeline towards
LG Chem, which absorbed LG Life Science, the bio and pharmaceutical subsidiary of LG Group, in 2017, is accelerating efforts to develop innovative new drugs such cancer, immune disorder and
Avacta’s Alastair Smith discusses their agreement with ADC Therapeutics, the Phase I AVA6000 trial, commercial opportunities, the recent placing and the performance of the Affimer reagents business unit in this exclusive interview with DirectorsTalk.
With the assistance of the company’s joint broker Turner Pope, Avacta is raising gross proceeds of up to £9m through the issue of up to 59.8 million new shares (including
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
